Evidence map›Paper›PMID 40084510›Full record

ArticleEuropean journal of haematology2025

Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.

Ahmad Y Abuhelwa, Sara A Almansour, Ethan Basch, Humaid O Al-Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad H Semreen, Zelal Kharaba, Salma M Ali, Rawan Mohamed and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ahmad Y AbuhelwaDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.ORCID https://orcid.org/0000-0002-4182-065X
Sara A AlmansourDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.
Ethan BaschLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Humaid O Al-ShamsiDepartment of Oncology, Burjeel Cancer Institute, Abu Dhabi, UAE.
Ziad AbuhelwaDepartment of Hematology and Medical Oncology, University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Yasser BustanjiCollege of Medicine, University of Sharjah, Sharjah, UAE.
Mohammad H SemreenDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.
Zelal KharabaDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.
Salma M AliDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.
Rawan MohamedDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.
Ganessan KichenadasseCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Ross A McKinnonCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Michael J SorichCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Karem H AlzoubiDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.
Ashley M HopkinsCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.

Funding

Tour De Cure, Australia RSP-117-FY2023University of Sharjah Targeted Research 2301110392
6 · The paper itself

Abstract

objectivesPatient-reported outcomes (PROs), including physical function, have predictive potential for survival but remain underexplored in multiple myeloma (MM). This study evaluates the predictive and prognostic value of PROs for treatment outcomes in MM patients on daratumumab-based therapy and evaluates physical function versus ECOG Performance Status as a potential treatment-effect modifier.

methodsData was pooled from randomized trials (MAIA, POLLUX, CASTOR) that collected pretreatment PROs using EORTC QLQ-C30. Cox models and logistic regression examined associations between PROs and overall survival (OS), progression-free survival (PFS) and grade ≥ 3 adverse events. Physical function versus ECOG-PS was examined as a treatment effect modifier for daratumumab versus non-daratumumab therapies.

resultsAmong 1804 patients, 1535 (85%) had pretreatment PROs. Physical function, global health, and fatigue were most prognostic for survival and adverse events. Physical function provided independent prognostic value beyond ECOG-PS and was predictive of treatment effect. Low physical function patients experienced greater OS treatment benefit (adjusted HR (aHR) [95% CI] 0.53 [0.40-0.70], p interaction = 0.02) and PFS (aHR [95% CI] 0.30 [0.30-0.48], p interaction = 0.03) from daratumumab versus high-physical function (OS aHR 0.86 [0.62-1.19], PFS aHR 0.53 [0.42-0.67]).

conclusionPhysical function is a predictive and prognostic marker that complements ECOG-PS, supporting its use in informing therapy decisions for daratumumab-based treatments.

Indexed as

Antibodies, MonoclonalMultiple MyelomaPatient Reported Outcome MeasuresAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPrognosisQuality of LifeTreatment OutcomeAntibodies, Monoclonaldaratumumabmultiple myelomaoverall survivalpatient‐reported outcomesprogression‐free survival

Identifiers

PMID40084510
PMCPMC12053969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.